Featured Content
Moving Targets: Off-Label Prescribing of Targeted Therapies
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
The Patient Behind the EHR: Oncologists Only See Half the Picture
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Who Determines What 'Value' Looks Like in Value-Based Cancer Care?
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.More Features>>>
Endocrine Cancer News
Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules
October 05, 2018
MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer
October 04, 2018
Endocrine Cancer Resources
More Information
Differences in Treatment Site of Care: Why Is My Insurer Sending Me to a Particular Treatment Center?
December 07, 2018
This fact sheet discusses the differences in cost between cancer care at physician offices and health system-based sites of care.
Cancer Recurrence Statistics
November 30, 2018
This fact sheet describes the estimated rates of recurrence of selected cancers.
Understanding Drug Approval and Researching Newly Approved Cancer Treatments
November 30, 2018
This fact sheet provides patient-focused information about the FDA drug approval process and guidance on researching FDA-approved agents for patients with cancer.
Palliative Care and Survivorship
November 16, 2018
This fact sheet discusses the importance of palliative care as it pertains to cancer survivorship.
Nutraceuticals/Supplements and Cancer Prevention: All Hype?
November 09, 2018
This fact sheet discusses the research on supplement use and cancer incidence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
- CAR-T and Ibrutinib: Better Together?
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type